Bile Acids in Patients with Uncontrolled Type 2 Diabetes Mellitus
                    – The Effect of Two Days of Oatmeal Treatment

Graciela E. Delgado; Bernhard K. Krämer; Hubert Scharnagl; Günther Fauler; Tatjana Stojakovic; Winfried März; Marcus Edi Kleber; Alexander Lammert

doi:10.1055/a-1069-7330

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 2020; 128(09): 624-630
DOI: 10.1055/a-1069-7330

Article

Bile Acids in Patients with Uncontrolled Type 2 Diabetes Mellitus – The Effect of Two Days of Oatmeal Treatment

Authors

Graciela E. Delgado

¹Fifth Department of Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
Bernhard K. Krämer

¹Fifth Department of Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
Hubert Scharnagl

²Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria
Günther Fauler

²Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria
Tatjana Stojakovic

³Clinical Institute of Medical and Chemical Laboratory Diagnostics, University Hospital Graz, Graz, Austria
Winfried März

¹Fifth Department of Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

²Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria

⁴Synlab Academy, Synlab Holding Deutschland GmbH, Mannheim, Germany
Marcus Edi Kleber ‡

¹Fifth Department of Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
Alexander Lammert‡

¹Fifth Department of Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

⁵Praxis für Diabetes, Stoffwechsel-und Nierenerkrankungen, Grünstadt, Germany

Abstract

Background Beta-glucans are effective in binding bile acids (BA) thereby lowering cholesterol concentration. This might contribute to the beneficial effects of the consumption of β-glucan-rich foods like oatmeal on glucose homeostasis.

Objective We measured BA serum concentrations in patients with uncontrolled type 2 diabetes (T2DM) to investigate the effect of two days of oatmeal treatment on BA concentration as compared to a conventional T2DM-adapted diet.

Methods The OatMeal And Insulin Resistance study was performed as a randomized, open label crossover dietary intervention study with consecutive inclusion of 15 patients in an inpatient clinical setting. Bile acids were measured by high-resolution mass spectrometry. For statistical analysis, the differences in the concentration of serum BA and laboratory parameters between the fifth day and the third day of each inpatient stay were calculated and the effect compared between both phases by using the Wilcoxon test.

Results Whereas there was a mean decrease in total BA following oatmeal treatment (−0.82±1.14 µmol/l), there was no decrease following the control treatment. Glycocholic acid was lower after oatmeal treatment but higher following control treatment (−0.09±0.17 vs. 0.05±0.11 µmol/l). The reduction in total BA was directly correlated with a decrease in proinsulin during the oatmeal phase. Decreases in blood lipids or apolipoproteins were mostly greater after oatmeal treatment, but these differences were not statistically significant.

Conclusion Two days of oatmeal diet led to significant reductions in total BA as compared to a diabetes-adapted control diet. The magnitude of BA reduction was directly correlated with a decrease in proinsulin.

Key words

beta-glucans - fibres - dietary intervention

Full Text

References

References
1 Stamp D, Jenkins G. An Overview of Bile-Acid Synthesis, Chemistry and Function. In: Jenkins G, Hardie LJ Eds Bile Acids - Toxicology and Bioactivity 1 ed. Cambridge, UK: Royal Society of Chemistry; 2008: 1-13
2 Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006; 47: 241-259. doi:10.1194/jlr.R500013-JLR200
3 Prawitt J, Caron S, Staels B. Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr Diab Rep 2011; 11: 160-166. doi:10.1007/s11892-011-0187-x
4 Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 1994; 121: 416-422 doi:10.7326/0003-4819-121-6-199409150-00004
5 Zieve FJ, Kalin MF, Schwartz SL. et al. Results of the glucose-lowering effect of WelChol study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007; 29: 74-83.
6 Zema MJ. Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action. Core Evid 2012; 7: 61-75. doi:10.2147/CE.S26725
7 Hansen M, Sonne DP, Mikkelsen KH. et al. Bile acid sequestrants for glycemic control in patients with type 2 diabetes: A systematic review with meta-analysis of randomized controlled trials. J Diabetes Complications 2017; 31: 918-927.
8 Kim HJ, White PJ. Interactional effects of beta-glucan, starch, and protein in heated oat slurries on viscosity and in vitro bile acid binding. J Agric Food Chem 2012; 60: 6217-6222. doi:10.1021/jf300786f
9 Hou Q, Li Y, Li L. et al. The metabolic effects of oats intake in patients with type 2 diabetes: A systematic review and meta-analysis. Nutrients 2015; 7: 10369-10387.
10 Delgado G, Kleber ME, Kramer BK. et al. Dietary intervention with oatmeal in patients with uncontrolled type 2 diabetes mellitus - A crossover study. Exp Clin Endocrinol Diabetes 2019; 127: 623-629
11 Amplatz B, Zohrer E, Haas C. et al. Bile acid preparation and comprehensive analysis by high performance liquid chromatography-high-resolution mass spectrometry. Clin Chim Acta 2017; 464: 85-92.
12 Bachorik PS, Ross JW. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin Chem 1995; 41: 1414-1420
13 Wanner C, Horl WH, Luley CH. et al. Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis. Kidney Int 1991; 39: 754-760.
14 Stojakovic T, Putz-Bankuti C, Fauler G. et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 2007; 46: 776-784.
15 [Anonymous] R Core Team. R: A language and environment for statistical computing. 2018;
16 Nyman M. Fermentation and bulking capacity of indigestible carbohydrates: the case of inulin and oligofructose. Br J Nutr 2002; 87 Suppl 2 : S163-: S168.
17 Thandapilly SJ, Ndou SP, Wang Y. et al. Barley beta-glucan increases fecal bile acid excretion and short chain fatty acid levels in mildly hypercholesterolemic individuals. Food Funct 2018; 9: 3092-3096.
18 Chambers ES, Preston T, Frost G. et al. Role of gut microbiota-generated short-chain fatty acids in metabolic and cardiovascular health. Curr Nutr Rep 2018; 7: 198-206.
19 Naumann S, Schweiggert-Weisz U, Eglmeier J. et al. In vitro interactions of dietary fibre enriched food ingredients with primary and secondary bile acids. Nutrients 2019; 11.
20 Gunness P, Gidley MJ. Mechanisms underlying the cholesterol-lowering properties of soluble dietary fibre polysaccharides. Food Funct 2010; 1: 149-155. doi:10.1039/c0fo00080a
21 Sembries S, Dongowski G, Mehrlander K. et al. Dietary fiber-rich colloids from apple pomace extraction juices do not affect food intake and blood serum lipid levels, but enhance fecal excretion of steroids in rats. J Nutr Biochem 2004; 15: 296-302.
22 Saga K, Iwashita Y, Hidano S. et al. Secondary unconjugated bile acids induce hepatic stellate cell activation. Int J Mol Sci 2018; 19.
23 Hanafi NI, Mohamed AS, Sheikh Abdul Kadir SH. et al. Overview of bile acids signaling and perspective on the signal of ursodeoxycholic acid, the most hydrophilic bile acid, in the heart. Biomolecules 2018; 8.
24 Sanchez-Garcia A, Sahebkar A, Simental-Mendia M. et al. Effect of ursodeoxycholic acid on glycemic markers: A systematic review and meta-analysis of clinical trials. Pharmacol Res 2018; 135: 144-149.
25 Gunness P, Michiels J, Vanhaecke L. et al. Reduction in circulating bile acid and restricted diffusion across the intestinal epithelium are associated with a decrease in blood cholesterol in the presence of oat beta-glucan. FASEB J 2016; 30: 4227-4238.
26 Ellegard L, Andersson H. Oat bran rapidly increases bile acid excretion and bile acid synthesis: an ileostomy study. Eur J Clin Nutr 2007; 61: 938-945. doi:10.1038/sj.ejcn.1602607
27 Rajani C, Jia W. Bile acids and their effects on diabetes. Front Med 2018; 12: 608-623. doi:10.1007/s11684-018-0644-x
28 Harach T, Pols TW, Nomura M. et al. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci Rep 2012; 2: 430.
29 Adrian TE, Gariballa S, Parekh KA. et al. Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers. Diabetologia 2012; 55: 2343-2347.
30 Wu T, Bound MJ, Standfield SD. et al. Effects of taurocholic acid on glycemic, glucagon-like peptide-1, and insulin responses to small intestinal glucose infusion in healthy humans. J Clin Endocrinol Metab 2013; 98: E718-E722.
31 Wu T, Horowitz M, Jones KL. et al. Endogenous glucagon-like peptide-1 mediates the lowering of glycaemia during small intestinal glucose infusion by bile acids in type 2 diabetes. Diabetologia 2017; 60: S92
32 Larraufie P, Roberts GP, McGavigan AK. et al. Important Role of the GLP-1 Axis for Glucose Homeostasis after Bariatric Surgery. Cell Rep 2019; 26: 1399-1408. e1396
33 Flynn CR, Albaugh VL, Cai S. et al. Bile diversion to the distal small intestine has comparable metabolic benefits to bariatric surgery. Nat Commun 2015; 6: 7715.
34 Sonne DP, Hansen M, Knop FK. Bile acid sequestrants in type 2 diabetes: Potential effects on GLP1 secretion. Eur J Endocrinol 2014; 171: R47-R65 doi:10.1530/eje-14-0154
35 Sansome DJ, Xie C, Veedfald S. et al. Mechanism of glucose-lowering by metformin in type 2 diabetes: Role of bile acids. Diabetes Obes Metab 2019;
36 Hansen M, Scheltema MJ, Sonne DP. et al. Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion. Diabetes Obes Metab 2016; 18: 571-580.
37 Chavez-Talavera O, Tailleux A, Lefebvre P. et al. Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease. Gastroenterology 2017; 152: 1679-1694. e1673
38 van Dijk TH, Grefhorst A, Oosterveer MH. et al. An increased flux through the glucose 6-phosphate pool in enterocytes delays glucose absorption in Fxr-/- mice. J Biol Chem 2009; 284: 10315-10323.
39 Ma K, Saha PK, Chan L. et al. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006; 116: 1102-1109.
40 Popescu IR, Helleboid-Chapman A, Lucas A. et al. The nuclear receptor FXR is expressed in pancreatic beta-cells and protects human islets from lipotoxicity. FEBS Lett 2010; 584: 2845-2851.
41 Dufer M, Horth K, Krippeit-Drews P. et al. The significance of the nuclear farnesoid X receptor (FXR) in beta cell function. Islets 2012; 4: 333-338.
42 Dufer M, Horth K, Wagner R. et al. Bile acids acutely stimulate insulin secretion of mouse beta-cells via farnesoid X receptor activation and K(ATP) channel inhibition. Diabetes 2012; 61: 1479-1489.

Supplementary Material

Supplementary Material (PDF)